{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:06:50Z","timestamp":1783958810690,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neutropenic fever (NF) is a common complication of systemic anti\u2010cancer therapy requiring prompt management. A previous 2009 Australian survey of NF clinical practices identified evidence\u2010practice gaps that informed the 2011 Australian Consensus Guidelines for the Management of Neutropenic Fever in Adult Cancer Patients. The emergence of novel cancer therapies and evidence for risk\u2010stratified NF treatment warrant re\u2010evaluation of current approaches to management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To describe current clinical practices in Australia and New Zealand in adult NF management, compare results to the 2009 survey, and identify areas for improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An electronic survey was distributed to haematology, oncology, and infectious diseases clinicians across Australia and New Zealand between June and August 2023. Survey domains included risk stratification, empiric treatment, use of prophylaxis, and management of patients colonised with multidrug\u2010resistant organisms. Descriptive analyses compared responses between specialties and to 2009 data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 132 clinician responses were received. Improvements were observed in the appropriateness of empiric treatment of NF with a reduction in the use of dual therapy and prescribing of antibacterial prophylaxis. However, knowledge of risk stratification and utilisation of ambulatory care for low\u2010risk NF remained low. Heterogeneity in empiric antibiotic duration and management of patients colonised with multi\u2010drug resistant organisms was observed. Infectious diseases involvement remained widespread but decreased among the medical oncology cohort between 2009 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While practices have evolved, critical gaps in risk assessment, appropriateness for early discharge, and antimicrobial stewardship remain. Investments in infrastructure, education and multidisciplinary collaboration are essential to improve the uptake of ambulatory care models for NF. The updated consensus guidelines have addressed ambulatory care, antimicrobial duration and empiric management of those colonised with resistant organisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.70273","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T04:35:54Z","timestamp":1768192554000},"page":"153-162","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Australasian survey of clinical practices in management of neutropenic fever in adult cancer patients 2023"],"prefix":"10.1111","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5264-2447","authenticated-orcid":false,"given":"Nikhil","family":"Singh","sequence":"first","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Pharmacy Department Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Lingaratnam","sequence":"additional","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle M.","family":"Haeusler","sequence":"additional","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Royal Children's Hospital  Melbourne Victoria Australia"},{"name":"Murdoch Children's Research Institute  Melbourne Victoria Australia"},{"name":"Department of Paediatrics University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Victorian Infectious Diseases Service The Peter Doherty Institute for Immunity and Infection, Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby P.","family":"Douglas","sequence":"additional","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases and Immunology Austin Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Thursky","sequence":"additional","affiliation":[{"name":"National Centre of Infections in Cancer Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases Peter MacCallum Cancer Centre  Melbourne Victoria Australia"},{"name":"Sir Peter MacCallum Department of Oncology University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Infectious Diseases University of Melbourne  Melbourne Victoria Australia"},{"name":"National Centre for Antimicrobial Stewardship, Department of Infectious Diseases University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02338.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30211-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04241-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05654-z"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12228"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14152"},{"key":"e_1_2_8_8_1","volume-title":"Australian Passive Antimicrobial Resistance Surveillance \u2013 Third\u2010Generation Cephalosporin Resistance in Escherichia coli and Klebsiella pneumoniae: Prevalence of Extended\u2010Spectrum B\u2010Lactamase (ESBL) Phenotype","author":"Australian Commission on Safety and Quality in Health Care","year":"2022"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2010.02342.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3038"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70237"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09693-0"},{"key":"e_1_2_8_13_1","article-title":"Outpatient treatment for people with cancer who develop a low\u2010risk febrile neutropaenic event","volume":"3","author":"Rivas\u2010Ruiz R","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1397-8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3921-3"},{"key":"e_1_2_8_16_1","unstructured":"National Centre for Infections in Cancer.No place like home (low\u2010risk febrile neutropenia program toolkit).2025. Available from URL:https:\/\/cancerandinfections.org\/low-risk-toolkit"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00145-4"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.2191"},{"key":"e_1_2_8_19_1","article-title":"Effect of antibiotics with anaerobic coverage on graft\u2010versus\u2010host disease in patients undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta\u2010analysis","author":"Ito H","journal-title":"Transpl Infect Dis"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7399.1111"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.09.020"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.70248"},{"key":"e_1_2_8_23_1","unstructured":"TiongA WhiteR WinterD DyetK.2019Survey of extended\u2010spectrum B\u2010lactamase\u2010producing Enterobacterales in New Zealand 2023."}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:24:40Z","timestamp":1783956280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/imj.70273"],"URL":"https:\/\/doi.org\/10.1111\/imj.70273","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}